Back
Also listed as
RHHBY
OTC
Day Range
$378.00
$397.80
52-Week Range
$288.90
$514.08
Volume
3
50D / 200D Avg
$450.02
/
$384.75
Prev Close
$375.75
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 24.6 | 0.4 |
| P/B | 9.4 | 2.9 |
| ROE % | 39.3 | 3.7 |
| Net Margin % | 20.9 | 3.8 |
| Rev Growth 5Y % | -0.5 | 10.0 |
| D/E | 1.0 | 0.2 |
Key Takeaways
Revenue declined -0.50% annually over 5 years
Earnings grew 55.69% over the past year
ROE of 39.30% indicates high profitability
Net margin of 20.94% shows strong profitability
Generating 14.09B in free cash flow
PEG of 0.39 suggests growth is underpriced
Growth
Revenue Growth (5Y)
-0.50%
Revenue (1Y)-1.36%
Earnings (1Y)55.69%
FCF Growth (3Y)10.95%
Quality
Return on Equity
39.30%
ROIC17.98%
Net Margin20.94%
Op. Margin26.59%
Safety
Debt / Equity
1.02
Current Ratio1.38
Interest Coverage12.13
Valuation
P/E Ratio
24.57
P/B Ratio9.36
EV/EBITDA21.11
Dividend Yield0.03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -1.36% | Revenue Growth (3Y) | 0.91% |
| Earnings Growth (1Y) | 55.69% | Earnings Growth (3Y) | 5.86% |
| Revenue Growth (5Y) | -0.50% | Earnings Growth (5Y) | -1.93% |
| Profitability | |||
| Revenue (TTM) | 61.55B | Net Income (TTM) | 12.89B |
| ROE | 39.30% | ROA | 12.79% |
| Gross Margin | 72.94% | Operating Margin | 26.59% |
| Net Margin | 20.94% | Free Cash Flow (TTM) | 14.09B |
| ROIC | 17.98% | FCF Growth (3Y) | 10.95% |
| Safety | |||
| Debt / Equity | 1.02 | Current Ratio | 1.38 |
| Interest Coverage | 12.13 | Dividend Yield | 0.03% |
| Valuation | |||
| P/E Ratio | 24.57 | P/B Ratio | 9.36 |
| P/S Ratio | 5.14 | PEG Ratio | 0.39 |
| EV/EBITDA | 21.11 | Dividend Yield | 0.03% |
| Market Cap | 316.65B | Enterprise Value | 345.52B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 61.55B | 62.40B | 60.44B | 63.28B | 62.80B |
| Net Income | 12.89B | 8.28B | 11.50B | 12.42B | 13.93B |
| EPS (Diluted) | 16.05 | 10.32 | 14.30 | 15.37 | 16.20 |
| Gross Profit | 44.89B | 46.11B | 44.08B | 42.88B | 43.15B |
| Operating Income | 16.37B | 13.42B | 15.40B | 17.48B | 18.16B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 100.75B | 101.80B | 90.47B | 88.15B | 92.32B |
| Total Liabilities | 62.85B | 65.64B | 57.21B | 56.14B | 63.97B |
| Shareholders' Equity | 33.82B | 31.77B | 29.32B | 27.99B | 24.49B |
| Total Debt | 34.45B | 36.35B | 30.78B | 26.54B | 32.55B |
| Cash & Equivalents | 5.58B | 6.98B | 5.38B | 4.99B | 6.85B |
| Current Assets | 38.75B | 40.04B | 33.45B | 33.82B | 35.63B |
| Current Liabilities | 28.01B | 27.02B | 24.82B | 27.24B | 38.42B |